# EDGAR Filing Document

**Accession Number:** 0000014272
**File Stem:** 0001140361-26-011729
**Filing Date:** 2026-3
**Character Count:** 4369
**Document Hash:** bf79da1a411ce418a0118b3842827375
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-011729.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0001140361-26-011729

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**EFFECTIVENESS DATE**: 20260327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRISTOL MYERS SQUIBB CO
- **CENTRAL INDEX KEY:** 0000014272
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 220790350
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-01136
- **FILM NUMBER:** 26807243

**BUSINESS ADDRESS:**
- **STREET 1:** ROUTE 206 AND PROVINCE LINE ROAD
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08543
- **BUSINESS PHONE:** 6092524621

**MAIL ADDRESS:**
- **STREET 1:** ROUTE 206 AND PROVINCE LINE ROAD
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08543

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BRISTOL MYERS CO
- **DATE OF NAME CHANGE:** 19891012

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### <br>

------

### FORM 15

#### <br>

------

#### CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

#### UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

#### OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

#### OF THE SECURITIES EXCHANGE ACT OF 1934.

#### Commission File Number: 000-54969

------

#### <br>

## BRISTOL-MYERS SQUIBB COMPANY

#### (Exact name of registrant as specified in its charter)

#### <br>

------

#### Route 206 & Province Line Road

#### Princeton, New Jersey 08543

#### Telephone: (609) 252-4621

#### (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

#### $2 Convertible Preferred Stock, $1 Par Value

#### (Title of each class of securities covered by this Form)

#### Common Stock, $0.10 Par Value

#### Celgene Contingent Value Rights

#### 3.200% Notes due 2026

#### 6.800% Notes due 2026

#### 1.125% Notes due 2027

#### 3.250% Notes due 2027

#### 3.450% Notes due 2027

#### 3.900% Notes due 2028

#### 3.400% Notes due 2029

#### 4.900% Notes due 2029

#### 1.450% Notes due 2030

#### 2.973% Euro Notes due 2030

#### 5.100% Notes due 2031

#### 5.750% Notes due 2031

#### 2.950% Notes due 2032

#### 3.363% Euro Notes due 2033

#### 5.900% Notes due 2033

#### 5.200% Notes due 2034

#### 1.750% Euro Notes due 2035

#### 5.875% Notes due 2036

#### 3.857% Euro Notes due 2038

**#### 6.125% Notes due 2038

#### 4.125% Notes due 2039

#### 2.350% Notes due 2040

#### 5.700% Notes due 2040

#### 3.250% Notes due 2042

#### 3.550% Notes due 2042

#### 5.250% Notes due 2043

#### 4.500% Notes due 2044

#### 4.625% Notes due 2044

#### 5.500% Notes due 2044

#### 4.289% Euro Notes due 2045

#### 5.000% Notes due 2045

#### 4.350% Notes due 2047

#### 4.550% Notes due 2048

#### 4.250% Notes due 2049

#### 2.550% Notes due 2050

#### 3.700% Notes due 2052

#### 6.250% Notes due 2053

#### 5.550% Notes due 2054

#### 4.581% Euro Notes due 2055

#### 3.900% Notes due 2062

#### 6.400% Notes due 2063

#### 5.650% Notes due 2064

#### 6.875% Notes due 2097

#### (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

####** 

<br> ------

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☐ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: Zero holders

------

Pursuant to the requirements of the Securities Exchange Act of 1934, Bristol-Myers Squibb Company has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: March 27, 2026 | **Bristol-Myers Squibb Company** | **Bristol-Myers Squibb Company** |
|  | By: | /s/ Amy Fallone |
|  | Name: | Amy Fallone |
|  | Title: | Senior Vice President and Corporate Secretary |

---

------